Threshold Pharmaceuticals Inc. (THLD)

Oncology Corporate Profile

Stock Performance


HQ Location

170 Harbor Way, Suite 300
South San Francisco, CA 94080

Company Description

Threshold is a biotechnology company focused on the discovery and development of therapeutics based on Tumor Hypoxia, a powerful scientific platform that offers broad potential to treat most solid tumors.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
evofosfamide (+ gemcitabine)bromo isophosphoramide mustard (Br-IPM) agentPancreatic CancerIII
evofosfamidebromo isophosphoramide mustard (Br-IPM) agentCholangiocarcinomaII
evofosfamide (+ bevacizumab)bromo isophosphoramide mustard (Br-IPM) agentGlioblastoma Multiforme (GBM)II
evofosfamide (+ sunitinib)bromo isophosphoramide mustard (Br-IPM) agentPancreatic neuroendocrine tumorsII
evofosfamide (+immune checkpoint inhibitors)bromo isophosphoramide mustard (Br-IPM) agentVarious cancer typesI
TH-3424AKR1C3 inhibitorAcute Lymphocytic Leukemia (ALL)Preclinical
TH-3424AKR1C3 inhibitorCastrate-resistant Prostate cancer (CRPC)Preclinical
TH-3424AKR1C3 inhibitorHepatocellular carcinoma (HCC)Preclinical

View additional information on product candidates here »


Recent News Headlines

Caris Life Sciences and Threshold Pharmaceuticals Collaborate to Utilize Caris’ ADAPT Biotargeting System in the Development Program for Evofosfamide

10/25/2016 05:33 pm

(Yahoo! Finance) Oct 25, 2016 - Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, and Threshold Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specializing in the development of novel pharmaceutical products for the treatment of cancer, today announced that they have entered into a development and commercialization agreement to utilize Caris’ patented and proprietary ADAPT Biotargeting System™ to develop a tissue-based clinical diagnostic assay for pancreatic cancer patients to predict the likelihood of response to evofosfamide, Threshold’s lead drug candidate for the potential treatment of patients with cancer.

World Health Organization Drops Coffee’s Status as Possible Carcinogen

6/15/2016 11:05 am

(Wall Street Journal) June 15, 2016 - Twenty-five years after classifying coffee as a possible carcinogen leading to bladder cancer, the World Health Organization’s cancer research arm has reversed course, saying on Wednesday that coffee is not classifiable as a carcinogen.

Threshold Pharmaceuticals Highlights Multiple Presentations at the 2016 ASCO Annual Meeting

6/6/2016 10:31 pm

(Threshold) June 6, 2016 - Presentation of additional subset data from Phase 3 MAESTRO trial of evofosfamide in pancreatic cancer demonstrates meaningful improvement in overall survival in patients from Asia; risk of death reduced by almost 50 percent.

One-Third of Clinical Trial Results Never Disclosed, Study Finds

2/18/2016 12:03 pm

(Bloomberg) Feb 17, 2016 - One-third of clinical trials conducted at 51 major U.S. universities and academic hospitals were never published in a peer-reviewed journal or in a government registry online, according to a new study in the BMJ, formerly the British Medical Journal.

FDA Sees Spike in Gene and Cell Therapy Applications

2/17/2016 12:01 pm

( Feb 16, 2016 - The US Food and Drug Administration’s Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) met Tuesday to discuss updates of research programs in the Office of Cellular, Tissue and Gene Therapy (CTGT), which is part of FDA’s Center for Biologics Evaluation and Research (CBER).

Threshold Pharmaceuticals and Merck KGaA, Darmstadt, Germany Agree to Key Terms for the Licensing Back of All Rights to Evofosfamide to Threshold

1/11/2016 12:55 pm

(CNN Money) Jan 11, 2016 - Threshold Pharmaceuticals, Inc. today announced an update on its evofosfamide program including that Threshold and Merck KGaA, Darmstadt, Germany have agreed upon key terms for the licensing back of all rights to evofosfamide to Threshold.

Threshold Pharmaceuticals Announces Workforce Reduction

12/21/2015 05:58 pm

(CNNMoney) Dec 18, 2015 - Threshold to focus on clinical trials of tarloxotinib while evaluating potential further development of evofosfamide and other strategic options for the company.

Merck KGaA, Threshold Drug Fails In Late-Stage Cancer Trials

12/7/2015 11:14 pm

(Reuters) Dec 7, 2015 -Germany's Merck KGaA and development partner Threshold Pharmaceuticals said their experimental cancer drug evofosfamide failed to extend lives in two late-stage clinical studies, a major setback for both firms.

Threshold Pharmaceuticals Announces Its Two Phase 3 Studies Evaluating Evofosfamide Did Not Meet Primary Endpoints

12/7/2015 12:49 pm

(CNNMoney) Dec 7, 2015 - Studies of evofosfamide combined With chemotherapy in advanced pancreatic cancer (MAESTRO) and advanced soft tissue sarcoma (TH-CR-406/SARC021) did not meet primary endpoints of improving overall survival with statistical significance.

Threshold Pharmaceuticals Enters Into Definitive Co-Promotion Agreement for Evofosfamide With Merck KGaA, Darmstadt, Germany

11/18/2015 05:54 pm

(CNNMoney) Nov 18, 2015 - Threshold Pharmaceuticals, Inc. today announced that it finalized a definitive Co-Promotion Agreement for evofosfamide with Merck KGaA, Darmstadt, Germany pursuant to the companies' License and Co-Development Agreement entered into on February 2, 2012.

Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial of Tarloxotinib Bromide (TH-4000) in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck or Skin

8/27/2015 04:46 pm

(MarketWatch) Aug 27, 2015 - Threshold Pharmaceuticals, Inc. today announced that the company has initiated a Phase 2 clinical trial of tarloxotinib bromide, or "tarloxotinib" (TH-4000), for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS).

Threshold Pharmaceuticals and ATOMIC Initiate First Phase 2 Clinical Trial of Tarloxotinib Bromide* (TH-4000) in Patients With Advanced EGFR-Mutant, T790M-Negative Non-Small Cell Lung Cancer (NSCLC)

8/11/2015 04:51 pm

(CNN Money) Aug 11, 2015 - Threshold Pharmaceuticals, Inc. today announced that the company, in collaboration with the Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC), has initiated the first Phase 2 clinical trial of tarloxotinib bromide, or "tarloxotinib" (TH-4000), for the treatment of patients with mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC) who have been previously treated with an EGFR tyrosine kinase inhibitor and are progressing on treatment, but have not acquired the T790M resistance mutation.

Shopping for a Doctor Who ‘Fits’

7/27/2015 12:00 pm

(New York Times/Well blog) July 23, 2015 - Decades ago, when physicians worked within a much more paternalistic system, “doctor shopping” by patients would have been considered inappropriate. Now it has become a routine part of my practice.

New Drug Sharply Lowers Cholesterol, but It’s Costly

7/27/2015 12:00 pm

(New York Times) July 24, 2015 - Federal regulators on Friday approved the first of a new class of drug that can sharply lower cholesterol levels, offering a new option for millions of Americans suffering from cardiovascular disease, the nation’s leading killer.

FDA Strengthens Heart Safety Warnings on Painkillers

7/10/2015 11:04 am

(NBC News) July 9, 2015 - The Food and Drug Administration is strengthening its warnings about painkillers like ibuprofen, saying they do raise the risk of heart attack or stroke.

Threshold Pharmaceuticals Presents Encouraging Preliminary Phase 2 Data in Multiple Myeloma at ASCO

6/1/2015 12:00 am

(Threshold) May 31, 2015 - Threshold Pharmaceuticals, Inc. today announced new preliminary data from the Phase 2 component of an ongoing Phase 1/2 trial of evofosfamide (an investigational compound formerly known as TH-302) in combination with the proteasome inhibitor Velcade® (bortezomib) and low-dose dexamethasone ("EBorD") in patients with relapsed/refractory multiple myeloma.

Celldex Builds Case for Brain Cancer Vaccine With New ASCO Data

5/31/2015 07:01 pm

(Xconomy New York) May 31, 2015 - Celldex Therapeutics grabbed the spotlight late last year when an experimental vaccine it’s been developing helped extend the lives of some patients with an aggressive, deadly form of brain cancer.

Biocept’s Blood-based Liquid Biopsy for Non-small Cell Lung Carcinoma Highlighted in American Society of Clinical Oncology (ASCO) Abstract

5/28/2015 12:02 pm

(StreetInsider) May 28, 2015 - Biocept, Inc., a molecular diagnostics company commercializing and developing liquid biopsies to improve the diagnosis and treatment of cancer, continues to build evidence of the clinical utility of its liquid biopsy offerings with an abstract at the 2015 Annual American Society of Clinical Oncology Meeting in Chicago starting on May 29, 2015.

Exercise Offers Cancer Survivors Significant Improvements in Quality of Life

5/28/2015 12:02 pm

(Yale News) May 28, 2015 - For many cancer survivors, a better quality of life is as close as the nearest pair of sneakers. That’s because a growing body of research, including two recent studies led by Yale Cancer Center, show that exercise is a powerful way for survivors to improve quality of life.

Myriad Validates Active Surveillance Threshold with Prolaris® for Men with Prostate Cancer

5/15/2015 05:31 pm

(MarketWatch) May 15, 2015 - Additional data show Prolaris changed treatment plans in 48 percent of cases.

Threshold Announces Clinical Update on Evofosfamide in Relapsed/Refractory Multiple Myeloma to Be Presented at ASCO 2015

5/14/2015 06:18 pm

(Yahoo! Finance) May 13, 2015 - Threshold Pharmaceuticals, Inc. today announced that new clinical data from its ongoing Phase 2 clinical trial evaluating evofosfamide (previously known as TH-302), an investigational compound, with bortezomib (Velcade®) and dexamethasone in patients with relapsed/refractory multiple myeloma.

Merck KGaA, Threshold Win Fast Track for Pancreatic Cancer Drug

5/12/2015 04:13 pm

(Fox May 12, 2015 - Germany's Merck KGaA said that experimental cancer drug evofosfamide, which it is jointly developing with Threshold Pharmaceuticals, won fast track status for the treatment of advanced pancreatic cancer from the U.S. Food and Drug Administration.

Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany, Receives FDA Fast Track Designation for Evofosfamide for the Treatment of Patients Living With Advanced Pancreatic Cancer

5/12/2015 12:07 pm

(CNN Money) May 12, 2015 - Threshold Pharmaceuticals, Inc. today announced that the FDA has granted Fast Track designation to the Company's partner Merck KGaA, Darmstadt, Germany, for the development of evofosfamide (previously known as TH-302), administered in combination with gemcitabine, for the treatment of previously untreated patients with metastatic or locally advanced unresectable pancreatic cancer.

A More Effective Shingles Vaccine Could Be on the Way for People Who Need It Most — Seniors

4/29/2015 12:00 pm

(Washington Post) Apr 28, 2015 - GSK says new shingles vaccine shows effectiveness across all age ranges, even those in their 70s.

Threshold Pharmaceuticals Reports Preclinical Data Suggesting That TH-4000 May Overcome Resistance to Conventional EGFR Tyrosine Kinase Inhibitors

4/22/2015 04:26 pm

(NASDAQ) Apr 22, 2015 - Threshold Pharmaceuticals, Inc. today announced preclinical data on TH-4000, its proprietary, molecularly-targeted, hypoxia-activated, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) suggesting that TH-4000 may overcome resistance to therapy with conventional EGFR-TKIs.

New Breath Test Detects Stomach Cancer

4/14/2015 12:00 pm

( Apr 14, 2015 - Scientists have discovered a new type of technology that senses compounds in exhaled breath that can be used as a screening tool to detect stomach cancer.

Novartis Accelerates Cancer Immunotherapy Efforts with Aduro Biotech Alliance and Launch of New Immuno-oncology Research Group

3/30/2015 06:04 am

(Novartis) Mar 30, 2015 - Novartis announced today that it is stepping up its efforts to harness the body's immune system to combat cancer. The company has entered into a major multiyear alliance with Aduro Biotech that is focused on the discovery and development of next generation cancer immunotherapies targeting the STING (Stimulator of Interferon Genes) pathway and launched a new immuno-oncology research group led by renowned cancer vaccine expert Glenn Dranoff, MD.

Cancer Immunotherapy 'Has Entered Mainstream'

3/26/2015 11:05 am

(Medscape Medical News) Mar 25, 2015 - Cancer immunotherapy takes centre stage in a series of articles about harnessing the immune system for therapy published March 25 as a special issue of Science Translational Medicine.

Lawmakers Said to Seek Medicare Fee Changes

3/16/2015 07:00 am

(Bloomberg) Mar 13, 2015 - The doctors who treat Medicare patients would avoid a cut in their government reimbursements under a proposal to be presented to U.S. House members next week, according to Republican and Democratic aides.

NCCN Recommends Only One Genomic Test For Breast Cancer

3/13/2015 11:03 am

(Medscape Medical News) Mar 12, 2015 - The National Comprehensive Cancer Network (NCCN) only endorses one genomic test for use in patients with early-stage breast cancer, according to a presenter here at the NCCN 20th Annual Conference.

Lilly Long-acting Insulin Delayed by Liver Concerns

2/23/2015 12:01 pm

(Reuters) Feb 23, 2015 - Eli Lilly and Co said it would postpone by at least two years the marketing application for its once-daily diabetes treatment to evaluate liver concerns, a delay some analysts said could doom the experimental drug.

Lung Cancer ‘Breathalyser' Goes Into Clinical Trials

2/19/2015 12:02 pm

(PharmaTimes [UK]) Feb 15, 2015 - A ground-breaking ‘breath test’ for lung cancer is about to go into clinical trials at Glenfield Hospital in Leicester, UK.

'Window of Vulnerability'

1/29/2015 11:01 am

(Harvard Medical School) Jan 28, 2015 - An existing drug may help some patients with non-small cell lung cancer (NSCLC) whose tumors have become resistant to chemotherapy, according to lab studies by Harvard Medical School researchers at Boston Children’s Hospital and the Dana-Farber Cancer Institute.

How, and Why, Chemists Figured Out How to Unboil an Egg

1/28/2015 12:00 pm

(Washington Post/Speaking of Science) Jan 28, 2015 - The eggs were used as a proxy for a much more serious endeavor: making cancer research more time and cost efficient.

Cancer-fighting CytomX Lands $20 Million Pfizer Investment, Makes Key Hires

1/6/2015 12:00 pm

(San Francisco Business Times) Jan 6, 2015 - CytomX Therapeutics Inc. grabbed $20 million from Pfizer Inc.'s venture capital arm to help partner its sneaky cancer fighters with new types of drugs and build out its own portfolio.

After CAR-T: Getting Ahead of the Next Hot Trend in Cancer Stocks

1/6/2015 12:00 pm

(TheStreet) Jan 6, 2015 - Here's how investors can help fund the next cure for cancer: anti-CD47 antibody therapies.

Threshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma

11/17/2014 05:18 pm

(MarketWatch) Nov 17, 2014 - 64% of patients achieved stable disease or tumor shrinkage on combination therapy following progression on single-agent bevacizumab; U.S. FDA set to fund phase 2 investigator-sponsored trial.

Threshold Pharmaceuticals Receives FDA Fast Track Designation for TH-302 for the Treatment of Previously Untreated Patients With Metastatic or Locally Advanced Unresectable Soft Tissue Sarcoma

11/11/2014 01:24 pm

(Yahoo! Finance) Nov 11, 2014 - Threshold Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for TH-302, an investigational anticancer drug, for the treatment of previously untreated patients with metastatic or locally advanced unresectable soft tissue sarcoma (STS).

Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany, Completes Target Enrollment in the TH-302 Phase 3 MAESTRO Study in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma

11/3/2014 05:59 pm

(Yahoo! Finance) Nov 3, 2014 - Threshold Pharmaceuticals, Inc., today announced that its partner Merck KGaA, Darmstadt, Germany, has completed target enrollment of 660 patients in the global Phase 3 MAESTRO (MetastAtic or unrESectable pancreaTic adenocarcinoma) study assessing the efficacy and safety of TH-302 in combination with gemcitabine in patients with previously untreated, locally advanced unresectable or metastatic pancreatic adenocarcinoma.

Cardinal Health Specialty Solutions, KEW Group Bring Power of Personalized Medicine to Community Oncologists

9/29/2014 09:05 am

(Cardinal Health) Sept 29, 2014 - Cardinal Health Specialty Solutions and KEW Group, Inc., a privately held oncology services company, today announced an agreement for the two companies to make KEW's state-of-the-art diagnostic services available to Specialty Solutions' community oncology customers.

AbbVie Presents Results From Multiple Studies of Investigational Compound Veliparib in Patients with Non-Small Cell Lung Cancer at the European Society for Medical Oncology Annual Congress

9/29/2014 09:01 am

(CNN Money) Sept 27, 2014 - AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free survival (PFS) and a 30 percent improvement (P-value=0.21) in overall survival (OS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC).

ZYTIGA® Plus Prednisone Demonstrates Statistically Significant Overall Survival After 49-Month Follow-Up Analysis in Chemotherapy-Naive Men With Metastatic Castration-Resistant Prostate Cancer

9/29/2014 09:01 am

(CNBC) Sept 28, 2014 - A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain showed that ZYTIGA® (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to an active control of placebo plus prednisone, in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC).